Search

everythinglearnresearchcommunity

for

Search:↓

Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.

Higher IL-31 levels are linked to worse itching in chronic kidney disease patients.

Smoking and certain health conditions like thyroid disease may make palmoplantar pustulosis harder to treat.

Different staff in a dermatology clinic understand mostly their own tasks, not the full clinic process.

Finasteride treatment lowers urine androgen and prostaglandin levels, making them potential markers for effectiveness.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

The ABI1 gene contributes to prostate cancer progression and treatment resistance.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.

Ruxolitinib helped a patient with alopecia areata regrow hair.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

Axitinib treatment turned a man's grey hair back to black.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.

The PTH-CBD injection improved hair regrowth better than the daily ruxolitinib pill in mice.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

Baricitinib might help treat hair loss in lupus patients, but more research is needed.